 OCALA, Fla., May 26, 2021 GLOBE NEWSWIRE -- AIM ImmunoTech Inc. NYSE American: AIM today announced that it has completed dosing of Cohort 3 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting no serious adverse events. 